ALEMBIC PHARMACEUTICALS
|
ALEMBIC PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 17.40 | 26.50 | 58.33 | 43.97 | 31.00 |
| CEPS(Rs) | 31.41 | 41.09 | 66.05 | 50.82 | 37.55 |
| DPS(Rs) | 8.00 | 10.00 | 14.00 | 10.00 | 5.50 |
| Book NAV/Share(Rs) | 222.36 | 266.47 | 257.80 | 170.79 | 144.24 |
| Tax Rate(%) | 3.56 | 16.70 | 18.52 | 19.92 | 20.92 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 12.53 | 16.48 | 27.44 | 26.36 | 21.75 |
| EBIT Margin(%) | 7.16 | 12.12 | 25.66 | 22.30 | 19.51 |
| Pre Tax Margin(%) | 6.27 | 11.79 | 25.37 | 21.71 | 19.04 |
| PAT Margin (%) | 6.05 | 9.82 | 20.67 | 17.38 | 15.06 |
| Cash Profit Margin (%) | 10.92 | 15.22 | 24.07 | 20.80 | 17.99 |
| Performance Ratios | |||||
| ROA(%) | 5.15 | 7.34 | 17.22 | 14.64 | 13.15 |
| ROE(%) | 7.12 | 10.11 | 26.91 | 26.97 | 24.00 |
| ROCE(%) | 7.44 | 11.25 | 26.28 | 23.30 | 22.66 |
| Asset Turnover(x) | 0.85 | 0.75 | 0.83 | 0.84 | 0.87 |
| Sales/Fixed Asset(x) | 1.73 | 1.97 | 2.31 | 2.52 | 2.85 |
| Working Capital/Sales(x) | 4.44 | 4.64 | 3.93 | 6.48 | 8.41 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.58 | 0.51 | 0.43 | 0.40 | 0.35 |
| Receivable days | 59.84 | 39.75 | 41.06 | 53.64 | 47.09 |
| Inventory Days | 99.60 | 106.49 | 90.48 | 85.38 | 78.91 |
| Payable days | 148.05 | 173.51 | 187.92 | 223.04 | 258.05 |
| Valuation Parameters | |||||
| PER(x) | 28.50 | 27.97 | 16.55 | 12.14 | 17.11 |
| PCE(x) | 15.79 | 18.04 | 14.61 | 10.50 | 14.13 |
| Price/Book(x) | 2.23 | 2.78 | 3.74 | 3.12 | 3.68 |
| Yield(%) | 1.61 | 1.35 | 1.45 | 1.87 | 1.04 |
| EV/Net Sales(x) | 1.82 | 2.85 | 3.59 | 2.55 | 2.78 |
| EV/Core EBITDA(x) | 14.49 | 16.37 | 12.35 | 9.55 | 12.37 |
| EV/EBIT(x) | 25.45 | 23.53 | 13.99 | 11.42 | 14.23 |
| EV/CE(x) | 1.70 | 2.09 | 2.78 | 1.96 | 2.21 |
| M Cap / Sales | 1.72 | 2.75 | 3.52 | 2.18 | 2.54 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.54 | -1.62 | 17.10 | 17.06 | 25.68 |
| Core EBITDA Growth(%) | -23.09 | -41.02 | 27.66 | 39.07 | 35.81 |
| EBIT Growth(%) | -37.06 | -53.53 | 34.77 | 33.77 | 40.95 |
| PAT Growth(%) | -34.35 | -53.27 | 39.23 | 35.11 | 40.78 |
| EPS Growth(%) | -34.35 | -54.56 | 32.66 | 41.83 | 41.62 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.15 | 0.12 | 0.10 | 0.54 | 0.42 |
| Current Ratio(x) | 1.78 | 1.63 | 1.89 | 1.41 | 1.28 |
| Quick Ratio(x) | 0.88 | 0.75 | 0.93 | 0.73 | 0.70 |
| Interest Cover(x) | 8.07 | 36.27 | 86.40 | 37.81 | 41.70 |
| Total Debt/Mcap(x) | 0.07 | 0.04 | 0.03 | 0.17 | 0.11 |
Compare Financial Ratios of peers of ALEMBIC PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALEMBIC PHARMACEUTICALS | ₹19,476.2 Cr | 4.9% | 3.6% | 83.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹360,920.0 Cr | -2.3% | -6.5% | 55.3% | Stock Analytics | |
| CIPLA | ₹113,794.0 Cr | 4.1% | -4.8% | 55.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹106,860.0 Cr | 7.8% | 17.4% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,316.0 Cr | 4% | 0.8% | 29.4% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,380.9 Cr | -1.2% | -5.2% | 83.9% | Stock Analytics | |
ALEMBIC PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALEMBIC PHARMACEUTICALS | 4.9% |
3.6% |
83.3% |
| SENSEX | 0.9% |
1.5% |
23.6% |
You may also like the below Video Courses
